

DAFTAR PUSTAKA

1. Liu YC, Kuo RL, Shih SR. COVID-19: The first documented coronavirus pandemic in history. Vol. 43, Biomedical Journal. Elsevier B.V.; 2020. p. 328–33.
2. Isbaniah F, Saputro DD, Sitompul PA, et al. Pedoman Kesiapsiagaan Menghadapi Coronavirus Disease (COVID-19) Revisi ke-3. Jakarta: Kementerian Kesehatan RI Direktorat Jenderal Pencegahan dan Pengendalian Penyakit; 2020:11
3. Shen K, Yang Y, Wang T. et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. World Journal of Pediatrics; 2020 Feb(16):223–224.
4. Khan S, Siddique R, Shereen MA, et al. Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options. Journal of Clinical Microbiology; 2020 May, 58;1-2.
5. Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jakarta: Jurnal Penyakit Dalam Indonesia, 2020; 1(7): 45-67
6. Park S. Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatric;2020:63(4):121–122.
7. Morawska L, Cao J. Airborne transmission of SARS-CoV-2: the world should face the reality. Environment International; 2020:139:1.
8. Lai, CC., Wang, CY., Wang, Y.H., et al. Global epidemiology of coronavirus disease 2019: disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. International Journal of Antimicrobial Agents. 2020; 55:1.
9. Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. (Review). 2020:1

10. Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. *Journal of Pharmaceutical Analysis*. 2020; 10:105-106
11. Tu. H, Tu. G, Gao. S, et al. Current epidemiological and clinical features of COVID-19; a global perspective from China. *Journal of Infection* 2020; 81:3
12. Rothhan H, Byrareddy S. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *Journal of Autoimmunity*. 2020; 109:2.
13. Peng F, Tu L, Yang Y, et al. Management and Treatment of COVID-19: The Chinese Experience. *Canadian Journal of Cardiology*. 2020
14. Tufan A, Güler A, Matucci-Cerinic M. COVID-19: immune system response, hyperinflammation and repurposing antirheumatic drugs. *Turkish Journal of Medical Sciences*, 2020 Apr 21; 50: 620-632. doi: 10.3906/sag 2004-168
15. Gennaro F, Pizzol D, Marotta C, et al. Coronavirus Disease (COVID-19) Current Status and Future Perspectives: A Narrative Review. *International Journal of Environmental Research and Public Health* 2020.
16. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infectious Disease of Poverty* 2020.
17. Cai H. Sex difference and smoking predisposition in patients with COVID-19. *Lancet Respir Med*. 2020;8(4):20.
18. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med*. 2020;8(4):21.
19. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Respir Med*. 2020;21(3):335–7.
20. Satuan Tugas Penanganan COVID-19, 2020. Peta sebaran 22 November 2020. Available at: <https://covid19.go.id/peta-sebaran>

21. Lisni I, Mujianti D, Anggriani A. ANTIBIOTIC PROFILE FOR COVID-19 TREATMENT IN A HOSPITAL IN BANDUNG. *Jurnal Ilmiah Farmako Bahari*. Bandung. 2021;12(2):101-103
22. Katzung BG. *Basic and clinical pharmacology*, Tenth Edition. Lange Medical Publications, United State.2016. p851-99.
23. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc*. 2020; 323 (11): 1–9.
24. Setiadi A, Wibowo Y, Halim, et al, Tatalaksana Terapi Pasien dengan COVID-19 sebuah kajian naratif, *Jurnal Farmasi Klinik Indonesia*, 2020;9(1): 70-94
25. Chorin E, Dai M, Shulman E, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. *Nat Med*, 2020;26(6):808-809.
26. Huang M, Tang T, Pang P, et al. Treating COVID-19 with chloroquine. *J Mol Cell Biol*. 2020;12(4):322-325.
27. Bimantara DE, Peran Vitamin C dalam pengobatan dalam pengobatan COVID-19 *Jurnal Majority*. 2020;9(10):123-126.
28. Widya A.P, Truly D.A, Gambaran Pengobatan Pasien Suspek Covid-19 Rawat Inap RS Brayat Minulya Surakara Periode-Oktober 2020, *Indonesia Journal On Medical Science*,2021;8(2): 114-117.
29. Chiba S, Effect of early oseltamivir outpatients without hypoxia with suspect COVID-19, *Wiener Klinische Wochenschrift*, 2020;1-6.
30. Aguila E, Cua I, Repurposed GI drugs in the treatment of COVID-19, *Digestive Diseases and sciences*. 2020;65(8): 2452-2453.
31. Ahmad N, Ferris J, Gooden E, et all. Making a case for domperidone in the treatment of gastrointestinal motility disorders. *Pharmaol*. 2006; 6:571-576.
32. Van Hecke O, Lee J. N-acetylcysteine: A rapid review of the evidence for effectiveness in treating COVID-19. *CEBM [Internet]*. 2020 April 14 [cited 2021 Jan 19]. Available :<https://www.cebm.net/covid-19/n-acetylcysteine-a-rapid-review-of-the-evidence-for-effectiveness-in-treating-covid-19/>

33. Qianwen Z, Yuanrong J, Yan M, Tao W. N-acetylcysteine improves oxidatives stress and inflammatory response in patients with community acquired pneumonia. *Medicine J.* 2018;97:45
34. Annane D. Corticosteroids for COVID-19. *J Intensive Med.* 2021;1-25.
35. Louvet S, Ischayek M, Danoff r. The current role of long-term benzodiazepines for the treatment of generalized anxiety. *20 Osteopathic Family Phsician.* 2015; 7(1):19-25.
36. Prajogo W, Prawesty D. A Case Report: Alprazolam Therapy in A Dextra Fronto-Parietal Mengioma Patient With Anxiety Disorders. *Medicra Journal of Medical laboratory Science Technology.* 2021;4(1):41-45.
37. Rico M, et al. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. *Current cardiology reports.* 2020;22(7):53-53.
38. Taofik R, Rizki A. Perkembangan Terkini Terapi Antikoagulan pada pasien COVID-19 dengan Gejala Berat. *Jurnal Sains Farmasi & Klinis.* 2020; 7(3): 244-250.
39. Hidayani W. Faktor Faktor Risiko yang Berhubungan Dengan COVID-19. *Literatur Riview, JUKMAS: Jurnal Kesehatan Masyarakat Sehat.* 202; 4(2): 120-134.
40. Skalny A, Rink L, Ajsuvakova O, Aschner M, et al. Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). *Int J Mol Med.* 2020;46(1):17-26.
41. Lydia F. Potensi Suplemen Dalam Tatalaksana COVID-19. *Continuing Mediical Education. Jakarta.* 2021;48(2): 93-96